NCT04024072View on ClinicalTrials.gov

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

PHASE3CompletedINTERVENTIONAL
Enrollment

495

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

April 30, 2020

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

Brinzolamide 1% ophthalmic suspension

Test product

DRUG

Azopt 1% Ophthalmic Suspension

Reference product

Trial Locations (1)

27101

James D. Branch Ophthalmology, Winston-Salem

Sponsors

Lead Sponsor

Padagis LLC
All Listed Sponsors
lead

Padagis LLC

INDUSTRY

NCT04024072 - To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes | Biotech Hunter | Biotech Hunter